| |
|
| |
|
 |
Safe
and effective use of insulin in hospitalised patients |
| |
The purpose of this document is to consider
the evidence and to make recommendations for trusts to follow to
ensure that insulin is used effectively and safely (NHS Diabetes) |
| |
|
|
The
hospital management of hypoglycaemia in adults with diabetes
mellitus |
| |
The aim of this guidance is to advise on the
the prompt and effective treatment and hospital management of hypoglycaemia
in adults with diabetes mellitus (NHS Diabetes) |
| |
|
|
The
management of diabetic ketoacidosis in adults |
| |
These guidelines have been developed to reflect
the development in technology and reflect new practice in the management
of DKA in the UK (NHS Diabetes) |
| |
|
|
Emotional
and psychological support and care in diabetes |
| |
This NHS Diabetes report explores the many issues
relevant to integrating emotional and psychological care within
diabetes services (NHS Diabetes) |
| |
|
|
Guideline
on self-monitoring of blood glucose in non-insulin treated type
2 diabetes |
| |
(International Diabetes Federation) |
| |
|
|
Guideline
on oral health for people with diabetes |
| |
(International Diabetes Federation) |
| |
|
|
Global
guideline on pregnancy and diabetes |
| |
(International Diabetes Federation) |
| |
|
|
Long-acting
insulin analogs and the risk of diabetic ketoacidosis in children
and adolescents with type 1 diabetes |
| |
Despite their long-acting pharmacokinetics,
the use of insulin glargine or detemir is not associated with a
lower incidence of DKA compared to NPH insulin (Diabetes Care) |
| |
|
|
Type
2 diabetes: postprandial hyperglycemia and increased cardiovascular
risk |
| |
Target levels of glucose control should be
individualized by focusing on both FPG and PPG and by optimizing
other risk factors of CVD, including high blood pressure, hyperlipidemia,
obesity, smoking, and poor exercise and dietary habits (Vascular
Health and Risk Management) |
| |
|
|
A
Cardiologist’s View of Hypoglycemia |
| |
In this article, we review the physiology of
glucose metabolism, the cardiovascular pathophysiology of hypoglycemia,
and the trials with an intensive glucose-lowering strategy that
have studied microvascular and macrovascular complications (Current
Atherosclerosis Reports) |
| |
|
|
Reducing
the risk of fatal and disabling hypoglycaemia: a comparison of
arterial blood sampling systems |
| |
Our study demonstrates that the closed-loop
arterial sampling system could be the universal solution sought
by the National Patient Safety Agency (British Journal of Anaesthesia) |
| |
|
|
DLife
Members Show Increased Use of Prescription Drugs to Treat Diabetes |
| |
Diabetes patients who use the multimedia network
dLife increased their use of prescription diabetes drugs by 1,600
percent compared with non-users (American Diabetes Association) |
| |
|
|
Surprising
findings about Hepatitis C and insulin resistance |
| |
Researchers at Garvan have now confirmed the
link between Hepatitis C and Type 2 diabetes - people with the
virus being 3 to 4 times more likely to develop diabetes, owing
to high levels of insulin resistance in muscle (Garvan Institute
of Medical Research) |
| |
|
|
Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients with Diabetes
Mellitus Trial |
| |
Bristol-Myers Squibb and AstraZeneca Announce
the Commencement of the Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus Trial (Market Watch) |
| |
|
|
Diamyd
US Phase III study well under way |
| |
The study will include 320 children and adolescents
between 10 and 20 years of age, recently diagnosed with type 1
diabetes (Diamyd) |
| |
|
|
Diabetes
Device Manufacturers Face New Regulations |
| |
A U.S. Food and Drug Administration push for
more accurate blood glucose meters for managing diabetes has caught
the attention of local device makers and developers testing next-generation
products (San Diego Business Journal) |
| |
|
|
Generex
Oral-lyn |
| |
Generex Establishes Key Strategic Relationships
for the Development of a Distribution Network for Generex Oral-lyn
under the FDA’s Expanded Access Treatment IND Program (PharmaLive) |
| |
|
